Treating Life-Threatening Bleedings

Development of Recombinant Coagulation Factor VIIa

Nonfiction, Health & Well Being, Medical, Specialties, Internal Medicine, Hematology
Cover of the book Treating Life-Threatening Bleedings by Ulla Hedner, Elsevier Science
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: Ulla Hedner ISBN: 9780128124406
Publisher: Elsevier Science Publication: July 4, 2017
Imprint: Academic Press Language: English
Author: Ulla Hedner
ISBN: 9780128124406
Publisher: Elsevier Science
Publication: July 4, 2017
Imprint: Academic Press
Language: English

Treating Life-Threatening Bleedings: Development of Recombinant Coagulation Factor VIIa provides a comprehensive understanding of the first new drug within the area of hemostasis, describing a new mechanism of action that has resulted in a modified concept of the whole hemostasis mechanism. As the treatment of life-threatening bleedings is a serious challenge for clinicians, this powerful and historic case study presents a detailed roadmap on how a new medicine can be developed, stressing the interaction between science and clinical work.

The book stresses the importance of patient care in the learning process and provides new ideas on how to approach diseases and their treatment. Users will find a real world example that will act as a timely resource for those learning about, or engaged in, performing and supervising research across the biomedical sciences.

  • Documents the successful roadmap of the development of a new concept of treating major bleedings in the most life-threatening situations
  • Stresses the importance of the close connection between the clinic and research, describing how a new concept of hemostasis was revealed by careful clinical observation
  • Offers real-world research and development context for drug discovery, and for the treatment of hemophilia and other bleeding disorders
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Treating Life-Threatening Bleedings: Development of Recombinant Coagulation Factor VIIa provides a comprehensive understanding of the first new drug within the area of hemostasis, describing a new mechanism of action that has resulted in a modified concept of the whole hemostasis mechanism. As the treatment of life-threatening bleedings is a serious challenge for clinicians, this powerful and historic case study presents a detailed roadmap on how a new medicine can be developed, stressing the interaction between science and clinical work.

The book stresses the importance of patient care in the learning process and provides new ideas on how to approach diseases and their treatment. Users will find a real world example that will act as a timely resource for those learning about, or engaged in, performing and supervising research across the biomedical sciences.

More books from Elsevier Science

Cover of the book Computational Materials Science by Ulla Hedner
Cover of the book Infections of the Nervous System by Ulla Hedner
Cover of the book Ecosystem Engineers by Ulla Hedner
Cover of the book Programmable Logic Controllers by Ulla Hedner
Cover of the book Rapidly Quenched Metals by Ulla Hedner
Cover of the book Synthetic Biology by Ulla Hedner
Cover of the book Engineering Materials 1 by Ulla Hedner
Cover of the book Nicotine and Other Tobacco Compounds in Neurodegenerative and Psychiatric Diseases by Ulla Hedner
Cover of the book Science and the Global Environment by Ulla Hedner
Cover of the book The Pearl Oyster by Ulla Hedner
Cover of the book Advances in Imaging and Electron Physics by Ulla Hedner
Cover of the book Statistical Mechanics by Ulla Hedner
Cover of the book Adsorption, Ion Exchange and Catalysis by Ulla Hedner
Cover of the book Progress in Heterocyclic Chemistry by Ulla Hedner
Cover of the book Entity Resolution and Information Quality by Ulla Hedner
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy